Canaccord reiterates Ionis stock rating on positive trial results

Ionis and Otsuka reported statistically significant Phase 3 results for Ulefnersen in FUS-ALS, including a positive primary endpoint, significant secondary endpoints and a favorable safety profile; Otsuka plans FDA discussions and expedited global submissions. Canaccord reiterated its Buy rating and $85 target versus IONS at $45.75, while projecting Ulefnersen revenue of $10 million in 2027 rising to $35 million in 2032. The positive rare-disease readout partly offsets recent setbacks, including pelacarsen's HORIZON trial failure and multiple analyst price-target cuts.

Analysis

Ulefnersen is strategically more valuable as an antisense-platform validation than as a near-term earnings driver. The addressable population is too small for the program to offset the value destruction from pelacarsen, so any sharp relief rally in IONS is likely to encounter sellers until management demonstrates that the broader commercial portfolio can replace the lost cardiovascular optionality. Otsuka, rather than IONS, controls launch execution; this also limits Ionis' ability to use a successful approval to independently accelerate revenue recognition or commercial leverage.

The relevant 1-3 month catalyst is FDA feedback on the registrational package, not the topline result itself. A path involving accelerated review could improve sentiment toward the RNA franchise, but it should not materially alter consensus cash-flow estimates absent revised royalty economics, launch timing, or a higher prevalence estimate. Over 6-18 months, the key valuation question remains whether Tryngolza uptake and the next late-stage pipeline assets can establish a durable post-pelacarsen growth trajectory; a weak initial launch would force another round of estimate cuts and reduce the platform premium.

Contrarianly, the market may be underpricing the signaling value of a placebo-controlled genetic ALS success after recent pipeline disappointment, particularly if FDA engagement is unusually rapid. But analysts assigning substantial value to this asset without modeling manufacturing, diagnosis, and patient-identification friction are likely overstating its contribution. The thesis is falsified positively by disclosed economics or guidance that makes the asset material to medium-term revenue, and negatively by any regulatory request for additional data or another reduction in 2026-27 commercial guidance.

Key Decisions for Investors

• Do not chase an initial IONS rally solely on the trial result; treat it as a sentiment catalyst rather than an earnings revision. Reassess after FDA meeting timing and royalty/launch disclosures, with a 1-3 month horizon.
• For biotech exposure, consider a tactical long IONS / short XBI pair only if IONS materially underperforms XBI into regulatory feedback despite unchanged commercial guidance. The trade isolates a potential platform re-rating; exit if Tryngolza launch metrics weaken or FDA requests additional Ulefnersen work.
• Set an earnings-monitoring trigger on management's 2026-27 revenue outlook and Tryngolza patient-start trajectory. A guidance increase or evidence of faster payer adoption supports adding exposure; a guidance cut should be viewed as confirmation that the pelacarsen valuation gap remains unfilled.
• Avoid assigning meaningful standalone valuation to Ulefnersen until Otsuka provides pricing, eligible-patient identification, and royalty details. Those variables, rather than trial statistics, determine whether the program can contribute enough cash flow to move IONS' multiple.